Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data
Autor: | Jeong Hoon Lee, Hyo Young Lee, Yun Bin Lee, Eun Ju Cho, Joon Hyeok Lee, S.-W. Kim, Jun Sik Yoon, Jung Hwan Yoon, Su Jong Yu, Young Chang, Yoon Jun Kim, Byeong Geun Song, Dong Hyun Sinn |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_treatment Immunotherapy Adoptive law.invention Cytokine-Induced Killer Cells 0302 clinical medicine Randomized controlled trial law Interquartile range Clinical endpoint Overall survival Adjuvant immunotherapy Cytokine-induced killer cell Liver Neoplasms Hazard ratio Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Combined Modality Therapy Survival Rate 030220 oncology & carcinogenesis Hepatocellular carcinoma Female Adjuvant Research Article medicine.medical_specialty Carcinoma Hepatocellular Transplantation Autologous lcsh:RC254-282 Disease-Free Survival 03 medical and health sciences Internal medicine Republic of Korea Genetics medicine Humans Propensity Score Aged Retrospective Studies business.industry Immunotherapy Recurrence-free survival medicine.disease 030104 developmental biology business Hepatocelluar carcinoma |
Zdroj: | BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019) BMC Cancer |
ISSN: | 1471-2407 |
Popis: | Background Several randomized controlled trials have shown that adjuvant immunotherapy with autologous cytokine-induced killer (CIK) cells prolongs recurrence-free survival (RFS) after curative treatment for hepatocellular carcinoma (HCC). We investigated the efficacy of adjuvant immunotherapy with activated CIK cells in real-world clinical practice. Methods A total of 59 patients who had undergone curative surgical resection or radiofrequency ablation for stage I or II HCC, and subsequently received adjuvant CIK cell immunotherapy at two large-volume centers in Korea were retrospectively included. Propensity score matching with a 1:1 ratio was conducted to avoid possible bias, and 59 pairs of matched control subjects were also generated. The primary endpoint was RFS and the secondary endpoints were overall survival and safety. Results The median follow-up duration was 28.0 months (interquartile range, 22.9–42.3 months). In a univariable analysis, the immunotherapy group showed significantly longer RFS than the control group (hazard ratio [HR], 0.42; 95% CI, 0.22–0.80; log-rank P = 0.006). The median RFS in the control group was 29.8 months, and the immunotherapy group did not reach a median RFS. A multivariable Cox proportional hazard analysis showed that immunotherapy was an independent predictor for HCC recurrence (adjusted HR, 0.38; 95% CI, 0.20–0.73; P = 0.004). The overall incidence of adverse events in the immunotherapy group was 16/59 (27.1%) and no patient experienced a grade 3 or 4 adverse event. Conclusions The adjuvant immunotherapy with autologous CIK cells after curative treatment safely prolonged the RFS of HCC patients in a real-world setting. Electronic supplementary material The online version of this article (10.1186/s12885-019-5740-z) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: |